Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
A Phase 1 Study Evaluating the Pharmacokinetics and Safety of Avacopan in Participants with End-Stage Kidney Disease on Hemodialysis.
Journal: Journal of clinical pharmacology
Published: December 23, 2025
An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Olpasiran in Chinese Participants With Elevated Serum Lipoprotein(a).
Journal: Clinical therapeutics
Published: May 13, 2025
Lack of Concentration-QTc Relationship and Cardiac Risk With Vatiquinone Therapeutic and Supratherapeutic Doses.
Journal: Clinical pharmacology in drug development
Published: May 09, 2024
Pharmacokinetic Drug-Drug Interaction Study of Omecamtiv Mecarbil With Amiodarone and Digoxin in Healthy Subjects.
Journal: Clinical pharmacology in drug development
Published: July 01, 2021
Healthy volunteers in first-in-human oncology drug development for small molecules.
Journal: British journal of clinical pharmacology
Published: June 02, 2021
Effect of Omecamtiv Mecarbil on the Pharmacokinetics of Metformin, a Probe Substrate for MATE1/MATE2-K, in Healthy Subjects.
Journal: Clinical drug investigation
Published: May 28, 2021
Relative Bioavailability of Omecamtiv Mecarbil Pediatric Minitablet Formulations in Healthy Adult Subjects.
Journal: Clinical drug investigation
Published: May 28, 2021
Pharmacokinetic Evaluation of the CYP3A4 and CYP2D6 Drug-Drug Interaction and CYP3A4 Induction Potential of Omecamtiv Mecarbil: Two Open-Label Studies in Healthy Subjects.
Journal: Clinical pharmacology in drug development
Published: April 27, 2021
Pharmacokinetic Drug-Drug Interaction Study of Omecamtiv Mecarbil With Omeprazole, a Proton Pump Inhibitor, in Healthy Subjects.
Journal: Clinical pharmacology in drug development
Published: April 16, 2021
Evaluation of drug-drug interaction potential between omecamtiv mecarbil and rosuvastatin, a BCRP substrate, with a clinical study in healthy subjects and using a physiologically-based pharmacokinetic model.
Journal: Clinical and translational science
Published: April 14, 2021
Switchability and minimal effect of food on pharmacokinetics of modified release tablet strengths of omecamtiv mecarbil, a cardiac myosin activator.
Journal: Biopharmaceutics & drug disposition
Published: March 23, 2021
Omecamtiv mecarbil does not prolong QTc intervals at therapeutic concentrations.
Journal: British journal of clinical pharmacology
Published: March 17, 2021
Last Updated: 09/26/2026